Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence - PubMed (original) (raw)
. 2007 Nov;51(2):399-406.
doi: 10.1111/j.1574-695X.2007.00321.x. Epub 2007 Aug 29.
Affiliations
- PMID: 17760875
- DOI: 10.1111/j.1574-695X.2007.00321.x
Free article
Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence
Lys Adriana Braga-Silva et al. FEMS Immunol Med Microbiol. 2007 Nov.
Free article
Abstract
Candida albicans is an opportunistic pathogen that is of growing medical importance because it causes superficial, mucosal and systemic infections in susceptible individuals. Here, the effect of suramin, a polysulfonated naphthylurea derivative, on C. albicans development and virulence was evaluated. Firstly, it was demonstrated that suramin (500 microM) arrested its growth, showing a fungicidal action dependent on cell number. Suramin treatment caused profound changes in the yeast ultrastructure as shown by transmission electron microscopy. The more important changes were the enlargement of the fungi cytoplasmic vacuoles, the appearance of yeasts with an empty cytoplasm resembling ghost cells and a reduction in cell wall thickness. Suramin also blocked the transformation of yeast cells to the germ-tube and the interaction between C. albicans and epithelial cells. In order to ascertain that the action of suramin on C. albicans growth is a general feature instead of being strain-specific, the effects of suramin on 14 oral clinical strains isolated from healthy children and HIV-positive infants were analyzed. Interestingly, the strains of C. albicans isolated from HIV-positive patients were more resistant to suramin than strains isolated from healthy patients. Altogether, the results produced here show that suramin interfered with essential fungal processes, such as growth, differentiation and interaction with host cells.
Similar articles
- Effects of IgY against Candida albicans and Candida spp. Adherence and Biofilm Formation.
Fujibayashi T, Nakamura M, Tominaga A, Satoh N, Kawarai T, Narisawa N, Shinozuka O, Watanabe H, Yamazaki T, Senpuku H. Fujibayashi T, et al. Jpn J Infect Dis. 2009 Sep;62(5):337-42. Jpn J Infect Dis. 2009. PMID: 19762981 - Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans.
Simonetti G, Passariello C, Rotili D, Mai A, Garaci E, Palamara AT. Simonetti G, et al. FEMS Yeast Res. 2007 Dec;7(8):1371-80. doi: 10.1111/j.1567-1364.2007.00276.x. Epub 2007 Jul 12. FEMS Yeast Res. 2007. PMID: 17627775 - Multiple effects of a novel compound from Burkholderia cepacia against Candida albicans.
Li X, Quan CS, Yu HY, Fan SD. Li X, et al. FEMS Microbiol Lett. 2008 Aug;285(2):250-6. doi: 10.1111/j.1574-6968.2008.01238.x. Epub 2008 Jun 28. FEMS Microbiol Lett. 2008. PMID: 18565124 - Adherence mechanisms of Candida albicans.
Cotter G, Kavanagh K. Cotter G, et al. Br J Biomed Sci. 2000;57(3):241-9. Br J Biomed Sci. 2000. PMID: 11050778 Review. - Human fungal pathogen Candida albicans in the postgenomic era: an overview.
Kabir MA, Hussain MA. Kabir MA, et al. Expert Rev Anti Infect Ther. 2009 Feb;7(1):121-34. doi: 10.1586/14787210.7.1.121. Expert Rev Anti Infect Ther. 2009. PMID: 19622061 Review.
Cited by
- Salivary proteins modulate Candida albicans virulence and may prevent oropharingeal candidiasis.
Curvelo JADR, Barreto ALS, Bayona-Pacheco BL, de Moraes DC, Portela MB, Ferreira-Pereira A, Adade CM, Souto-Padrón T, Soares RMA. Curvelo JADR, et al. Braz J Microbiol. 2024 Dec;55(4):3811-3825. doi: 10.1007/s42770-024-01517-5. Epub 2024 Sep 25. Braz J Microbiol. 2024. PMID: 39320637 - HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos.
Dos Santos AL. Dos Santos AL. World J Biol Chem. 2010 Feb 26;1(2):21-30. doi: 10.4331/wjbc.v1.i2.21. World J Biol Chem. 2010. PMID: 21537366 Free PMC article. - Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from _Candida albicans_-In Silico, In Vitro and In Vivo Approaches.
Santos ALS, Braga-Silva LA, Gonçalves DS, Ramos LS, Oliveira SSC, Souza LOP, Oliveira VS, Lins RD, Pinto MR, Muñoz JE, Taborda CP, Branquinha MH. Santos ALS, et al. J Fungi (Basel). 2021 May 28;7(6):424. doi: 10.3390/jof7060424. J Fungi (Basel). 2021. PMID: 34071195 Free PMC article. - The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site.
Morgan HP, McNae IW, Nowicki MW, Zhong W, Michels PA, Auld DS, Fothergill-Gilmore LA, Walkinshaw MD. Morgan HP, et al. J Biol Chem. 2011 Sep 9;286(36):31232-40. doi: 10.1074/jbc.M110.212613. Epub 2011 Jul 5. J Biol Chem. 2011. PMID: 21733839 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources